Objective: To examine the proportion of diabetic peripheral neuropathy (DPN) patients receiving pharmacologic DPN treatments and specifically to identify the rates and factors associated with opioid use and first-line opioid use.
D iabetes is the leading cause of morbidity and is the fifth leading cause of death in the United States. 1 Diabetic complications are the major cause of mortality and increases health care cost in the United States. 2 Diabetic neuropathy is a common complication of diabetes mellitus, caused by decreased blood flow and hyperglycemia. Almost 66% of type I and 59% of type II patients have diabetic neuropathy and 20% of all diabetic patients experience chronic neuropathic pain (NP). 3, 4 According to the International Association for the Study of Pain, 4 diabetic peripheral neuropathy (DPN) is defined as "pain initiated or caused by a primary lesion or dysfunction in the nervous system." The pain associated with DPN is often described as burning, stabbing, tingling, numbness, or itching, and is typically worse at night. Untreated or poorly managed DPN often leads to foot ulceration and lower extremity amputations. 5, 6 DPN is responsible for impaired healthrelated quality of life, and mental and physical well-being. About 12.5% of DPN patients remain unreported after diagnosis and 39% do not receive any treatment for DPN. 7 Current pharmacotherapy for DPN includes tricyclic antidepressants, anticonvulsants, nonsteroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase 2 inhibitors (COX 2) inhibitors, antiarrhythmics, benzodiazepines, and opioids. 8, 9 Only duloxetine, a selective serotonin norepinephrine reuptake inhibitor, and pregabalin, an anticonvulsant, are currently approved by the Food and Drug Administration (FDA) for treating DPN. 10 Currently, none of the neuropathy treatment guidelines recommend opioid as an initial choice for patients with DPN. [11] [12] [13] [14] [15] [16] All recommend antidepressants as first-line and anticonvulsants as first-line or second-line agents to treat NP. Tramadol and opioids are generally recommended for moderate to severe pain as third-line agents.
Use of opioids in noncancer painful conditions (NCPCs) has been studied, [17] [18] [19] but limited information is available about DPN and opioid usage. Currently, it is not known how widely opioids are used to treat DPN in a large representative population, nor do we have an understanding of the factors associated with the decision to initiate opioids. 20, 21 To our knowledge, no published studies have studied DPN/neuropathy guideline concordance with regard to opioid use. The goal of this study was to study the proportion of DPN patients who are prescribed pharmacologic treatments with a focus on opioid use and to determine the proportion of DPN patients who are prescribed opioids as first-line treatment. The factors associated with any or firstline opioid uses in DPN were also studied. This study further sought to describe the opioid use patterns and describes the duration and dose pattern of opioids (for schedule II long-acting, schedule II short-acting, schedule III-IV short-acting, and combinations of different opioid types), and the average daily dose expressed in morphine equivalents.
METHODS

Study Design and Data Source
A 10% random sample of IMS-LifeLink Health Plan claims data from 1998 to 2008 was analyzed using a retrospective longitudinal study design. The study data and study procedures were approved by institutional review board of the University of Arkansas for Medical Sciences. The LifeLink database is comprised of commercial health plan information obtained from over 98 managed care plans and represents the commercially insured population of the United States. This database is representative of the national commercially insured population in terms of age, sex, and geographic location.
Identification of the Study Sample
We identified DPN patients based on an ICD-9-CM diagnosis based validated DPN identification algorithm developed by Hartsfield et al. 22 This ICD-9-CM algorithm was validated with patient chart information and the reported sensitivity, specificity, positive predictive value, and negative predictive value were 94%, 55%, 64%, and 92%, respectively, indicating that it was capable of detecting most patients with DPN. Using the algorithm, diabetic patients were first identified based on the presence of one or more primary or secondary ICD-9-CM codes for diabetes (250.0xs-250. 5x and 250.7x-250.9x) and/or had received an antidiabetic agent (Appendix 1, Supplemental Digital Content 1, http://links.lww.com/CJP/A118) identified between January 1, 1998 through December 31, 2008. Once diabetic patients were identified, we used the algorithm described in Figure 1 to identify DPN patients. The index diagnosis was the first diagnosis of DPN (ICD-9-CM 250.6, 337.1, 337.9, 354.9, 355.8, 356.9, and 357.2) for persons that met the DPN inclusion criteria described in Figure 1 .
Once DPN patients were identified the following additional inclusion criteria were applied to ensure persons were eligible and accessing their pharmacy benefits, were adults, and were ambulatory. Patients had to be aged 18 years and older, have continuous plan and pharmacy benefit enrollment in the pre and post 12-month index periods, no nursing home or hospice care claims, and had at least 1 prescription claim in the postindex period. According to the initial study plan, we were to exclude patients who had opioid exposure before their index diagnosis. However, we discovered that many patients initiated DPN pharmacologic treatments before their first DPN diagnosis. Considering this finding, we chose to include patients with prior opioid and other DPN pharmacologic treatments therapy in the preindex period and chose to exclude persons who had a diagnosis for an indication for DPN pharmacologic treatments (depression, bipolar, epilepsy and anxiety, cancer, or painful condition) at any time in our primary analysis. The pain conditions considered were cancer (excluding nonmelanoma skin cancer), surgery, pain (headache/migraine, neck pain, back pain, abdominal pain, kidney stone, pelvic pain, rheumatoid arthritis, fracture/ contusions and temperomandibular joint pain, and arthritis/ joint pain (Appendix 2, Supplemental Digital Content 2, http://links.lww.com/CJP/A119).
Study Measures
Data on demographic and plan characteristic (age, sex, geographic location, insurance payer, and product type) were recorded from the plan enrollment file. Clinical characteristics of the DPN patients based on ICD-9-CM diagnosis codes were abstracted from the medical claims file for the preindex and postindex 12-month DPN diagnosis period. To measure overall medical comorbidity, the Charlson comorbidity index was used. 23 To get a measure of NCPCs in the sensitivity analyses that included these patients (see below), we counted the number of unique pain types persons had; headache/ migraine, neck pain, back pain, abdominal pain, kidney stone, pelvic pain, rheumatoid arthritis, fracture/contusions, temperomandibular, and arthritis/joint pain were used. Mental health and substance use disorders were recorded using ICD-9-CM codes developed by validated grouping software developed by the Agency for Healthcare Research and Quality. 24 A count of the number of types of metal health conditions (adjustment, depression, anxiety, mood, personality, and miscellaneous disorders) was created and used in the regression models of the sensitivity analysis cohorts. The most frequent type of physician seen by each patient was categorized into 4 categories; general practitioner/family practitioner/internal medicine, endocrinologists, podiatrists, and other prescribers based on the most frequent prescriber observed in the prescription claims. For persons who were prescribed DPN drugs, this was the most frequent prescriber type for DPN drugs and those not prescribed DPN drugs the most frequent prescriber of all other prescription claims.
Opioids, antidepressants, anticonvulsants, NSAIDs, topical agents, and skeletal muscle relaxants were considered DPN treatments and data on these were obtained from the pharmacy claims file and identified based on GPI codes (Appendix 3, Supplemental Digital Content 3, http://links. lww.com/CJP/A120). As these drugs have indications for conditions other than DPN and there is no linkage between a drug and its primary use in the data source, we developed a schema to classify those drugs as "DPN Related" if they met the following rules developed by the research team including a clinical pharmacist ( Fig. 2 ). If there are no DPN drug prescriptions in the preindex (365 d) period, then the DPN drug is presumed to be used for DPN and was classified as "DPN-related drug use." If the first DPN drug exposure was in the 120-day period before the index DPN diagnosis AND the patient had at least 1 prescription claim for any DPN drug in the postindex 365 days period, then that drug was presumed to treat DPN. The 120-day prediagnosis window was based on the premise that DPN drug treatments may be initiated to manage pain before a clinical encounter in which DPN is diagnosed. If the first prescribed DPN drug in the 365-day period before the index diagnosis, and that same drug is also prescribed in the 120-day period before the index diagnosis, and the patient also had at least 1 prescription claim for any DPN drug/s in the postindex 365 days period, then that drug was presumed to treat DPN. The first drug to meet the definition of DPN related was considered first-line use. Use of these drugs that did not meet any of the DPN-related definitions was presumed not to treat DPN and was considered "non-DPN related."
We describe the DPN drug use that occurred in the postindex 12 months as postindex DPN-related drug use. The sum of preindex DPN-related and postindex DPNrelated drugs was described as total DPN-related drug use, and "any use" that included DPN-related and nonrelated use. DPN patients with no DPN drug use in the preindex and postindex 12-month period are characterized as DPN patients with no pharmacologic treatment. DPN treatment initiation time was calculated as the difference between the date of the first-line DPN drug prescription and the index DPN diagnosis date for those who initiated therapy after their DPN diagnosis. For those that initiated DPN treatment before the DPN index date, a time to initiation was not calculated. Because opioid use was of specific interest to this study, we report exclusive use of opioids if opioids were the only DPN drug(s) prescribed in the preindex and postindex 12-month period. Chronic opioid use is defined as >90 days of opioid use with <32 days of gap between the last date of an early prescription and the fill date of the next prescription. If there were multiple prescriptions on the same fill date, we used the maximum value of days' supply for that fill date. We
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ICD-9 Inclusion Codes (250.6, 337. 1, 337.9, 354.9, 355.8, 355.9, 356.9, 357 calculated the cumulative and average daily opioid dose in morphine equivalent (MEq) based on opioid usage. 25 MEq was calculated by multiplying the quantity of each prescription by the opioid strength of the prescription and multiplying this product by a morphine equivalent conversion factor. If quantity was given and days' supply was missing for a prescription, MEq was calculated for that prescription but average daily dose was not calculated.
Analysis
For all study cohorts we obtained and reported the baseline descriptive characteristics for DPN treatment receivers, no treatment receivers, and any opioid receivers. Multivariable logistic regression models were estimated to explore factors associated with DPN pharmacologic treatment, any DPN-related opioid use, first-line opioid, and chronic opioid use. These models were estimated hierarchically, where the entire sample was used to identify factors associated with any DPN pharmacologic treatment. The models identifying factors associated with DPN-related opioid use and first-line opioid use were estimated for only those that had any DPN pharmacologic treatment and excluded those without any use. The chronic use models were only estimated for opioid users. Estimates of the odds ratios (OR) and 95% confidence intervals are reported. All analysis was carried out using SAS version 9.2 (SAS Institute, Cary, NC).
Sensitivity Analyses
We varied our inclusion criteria in a series of sensitivity analyses that primarily explore the certainty that drugs used to treat DPN were being used to treat DPN. The first sensitivity analysis was further restricted to exclude persons with any preindex opioid exposure thus diminishing the possibility that opioids were used to manage some other pain. With this cohort we have the greatest confidence that opioid use observed would be to treat DPN and not some other condition. We then progressively relaxed our inclusion criteria to include persons who had other If there is no DPN drug use in the 12-month preindex period, the first drug used after an index DPN diagnosis in the postindex 12-month period is described as the DPNrelated drug, in this example it is opioid. Decision rule 2: If a first DPN drug is used in a 120-day period before the index DPN diagnosis and the patient had at least 1 prescription claim for any DPN drug use in the postindex 12-month period then the first drug is characterized as a DPN-related drug. In this example, it is anticonvulsants. Decision rule 3: If a first DPN drug used in the preindex 12month period is also used in preindex120 days of index DPN diagnosis and the patient had at least 1 prescription claim for any DPN drug in the postindex 12-month period, then the first drug used is characterized as a DPN-related drug, in this example it is antidepressants. The first drug to meet the definition of DPN related was considered as first-line DPN drug use. AC indicates anticonvulsants; AD, antidepressants; NS, NSAIDs (nonsteroidal anti-inflammatory drugs); OP, opioid.
potential uses for opioids (pain diagnoses, surgery, and cancer) and these are described in the bottom of Figure 1 .
Multivariable logistic regression models were estimated for each sensitivity analysis cohort for the DPN drug use measures previously described.
RESULTS
A total of 363,241 diabetic patients were initially identified from the administrative claims and 666 met all the inclusion criteria ( Fig. 1 ). Of those that were retained, DPN pharmacologic treatment was observed for 354 (53.15%) patients and 288 (43.24%) had DPN-related drug use (Table 1) . Persons treated with a pharmacologic DPN drug were more likely to be from the west, and have diabetes with organ damage (P < 0.05). Compared with those who received nonopioid DPN pharmacologic treatments, persons prescribed opioids were more likely to have diabetes with organ damage, nephropathy, and higher comorbidity burden (P < 0.05) ( Table 2 ). Of those who received DPN pharmacologic treatment, 154 (53.47%) had DPN-related opioid use ( Table 2 ). The most common first-line agents used for DPN wAll DPN drugs used with or after the first-line DPN drug(s) was described as the DPN-related drug use. DPN indicates diabetic peripheral neuropathy; FP, family practice; GP, general practitioner; HMO, health maintenance organization; Indem, indemnity plan; PPO, preferred provider organization; PS, point of service.
were; opioids 33.33% (n = 96), antidepressants 26.39% (n = 76), anticonvulsants 22.57% (n = 65), NSAIDs 19.09% (n = 55), and skeletal muscle relaxants 5.21% (n = 15). FDAapproved agents duloxetine 1.04% (n = 3) and pregabalin 5.56% (n = 16) were used infrequently ( Table 3 ). The most frequently prescribed first-line opioids were; hydrocodone combinations 14.93% (n = 43) and oxycodone 6.94% (n = 20) ( The results from the multivariate logistic regression showed that patients from the west (OR = 1.89; 95% confidence interval [CI], 1.01-3.53), used insulin (OR = 1.49; 95% CI, 1.02-2.16) were more likely to receive a 
Sensitivity Analysis Results
Our first sensitivity analysis that excluded patients with prior opioid use included 464 patients and 37.07% (n = 172), 13.58% (n = 63), and 8.41% (n = 39) had DPN-related drug use, DPN-related opioid use, and first-line opioid use, respectively. As we relaxed the exclusion criteria and incrementally added the excluded conditions, DPN-related drug use and DPN-related opioid usage increased; 57.83% and 26.31% for the sensitivity analysis that included persons with pain conditions had DPN-related drug and DPN-related opioid use, respectively, and these same measures were 61.12% and 32.45% for the sensitivity analysis that also included patients with cancer and surgery, and were 70.61% and 49.29% for our most liberal cohort of 5792 patients who had no pain, surgery, cancer, or prior opioid restrictions. DPN patients with pain diagnoses and higher disease burden were more likely to receive DPN-related opioids, for longer durations and at higher doses in the patients with pain or surgery/cancer groups. In addition, as the DPN patients in the first 3 sensitivity analyses did not have preindex opioid exposure, first-line opioid use was not associated with pain diagnoses or the count of pain conditions (data not shown).
In the sensitivity cohorts with pain, cancer, surgery, and prior opioid exposure we consistently found that middle-aged and older people were less likely to have DPN-related opioids compared with the DPN patients with age of 18 to 40 years (P < 0.05). Also in these groups, midwest and west regions had higher DPN-related opioid use compared with the patients from the east. The count of pain conditions was strongly related with the DPN-related opioid in the sensitivity analysis cohorts with pain, cancer, surgery, and prior opioid use conditions. In our most restricted cohort, we observed *Prescription claim for (topical, anticonvulsants, opioids, antidepressants, skeletal muscle relaxants, and ion channel blockers) use in the preindex/ postindex 12-month period.
wAll DPN drugs used with or after the first-line DPN drug(s) in the pre/post 12 months. zDPN drug use in the 12-month post-DPN diagnosis. yFirst-line DPN drug as per the first-line DPN drug selection criteria. DPN indicates diabetic peripheral neuropathy; NSAID, nonsteroidal anti-inflammatory drugs; SNRI, serotonin norepinephrine reuptake inhibitors; SSRI, selective serotonin reuptake inhibitors; TCAs, tricyclic antidepressants. that females were more likely to receive first-line opioid use (OR = 3.62; 95% CI, 1.354-9.659) which is in contrast to our findings from other sensitivity analyses in which females had lower rates of first-line opioid use.
DISCUSSION
This is the first study to explore opioid use in the pharmacologic treatment of DPN. We found that 57% DPN patients did NOT receive any pharmacologic treatment that could be used for DPN, which is lower than most other studies that have described the rates of pharmacologic treatment of DPN patients. 26, 27 The rates we observed may reflect possible undertreatment or may be due to other factors. Our study did not account for over-the-counter pain medicines or other nonpharmacologic treatment options from the claims data. In addition, the DPN patients with the most common comorbidities: low back pain, arthritis/joint pain, depression, and anxiety disorders were excluded to define the primary cohort; this rate can be viewed as a lower bound of DPN pharmacologic treatment. Also, the previous studies describing the DPN treatment rates used surveys or cross-sectional data to estimate the DPN prevalence and treatments which might also explain the higher DPN pharmacologic treatment rates than our rates which followed persons for 1 year after their initial DPN diagnosis.
Despite the neuropathy treatment guidelines that discourage use of opioids as first-line treatment, opioids were used by over 50% of persons receiving a DPN pharmacologic treatment and opioids were the most frequently prescribed first-line agents and is consistent with a recent study, that showed that opioids were used as first-line agents in 28% of DPN patients. 28 This finding was robust across all of our sensitivity analyses. Further, we observed the mean initiation time in days for opioids was almost half compared with nonopioid DPN drugs which further demonstrate prescribers' preference for opioids over nonopioids in DPN. Approximately half of patients prescribed opioids used them exclusively while the remainder used opioids in conjunction with another DPN pharmacologic treatment. Also, all but 3 patients used opioids on a short-term basis (< 90 d) , so it appears that physicians use opioids as an acute analgesic strategy and frequently initiate opioids without trying alternative guideline-recommended therapies to manage DPN at the outset. Duloxetine (2004) and pregabalin (2005) are the only agents approved by the FDA for the treatment of DPN 29 ; however, these drugs were used infrequently in this sample. On one hand this is concerning because prescribing opioids can lead to misuse, abuse, dependency, tolerance, and potentially to increased mortality due to overdose of opioids. 30 On the other hand, we found that few persons used opioids on a chronic basis. High rates of concurrent opioid use have also been found in DPN patients treated with pregabalin. Practitioner choice of prescription opioids for NCPC continues to increase posing serious challenges for health care practitioners and policy makers. 19 Currently, about 90% to 95% of opioids are prescribed for NCPCs. 17 Increases in rates of diagnosis of NCPCs, use of prescription opioids, and increased cumulative yearly doses for NCPC patients have also been observed. 31 Opioids are very potent analgesics, whose abuse and accidental overdose are responsible for many ER visits and deaths 30 prompting the FDA to develop Risk Evaluation and Mitigation Strategies for certain opioid products. 32 The evidence regarding the use of opioids in managing NP conditions requires balancing risks and benefits. A recent Cochrane review assessed the efficacy and safety of opioids in the management of NP and found that opioids reduced pain more than placebo but was associated with increased adverse effects such as constipation, drowsiness, and nausea, and vomiting. 33 Opioids used in conjunction with nonopioids could achieve better analgesia with lower individual doses but may be offset by opioid-related side effects. 34 These studies provide evidence that opioids can alleviate the pain associated with DPN for those who can tolerate the side effects; however, the risk benefit profile of opioids used chronically over years is unknown and must be weighed against the increasing risk of opioid misuse and abuse that is a concern when treating any type of pain.
NSAIDs are not considered as drugs of choice in the chronic NP conditions including DPN. 35, 36 However, we found high usage of NSAIDs in treating DPN, which is consistent with previous research. 37 Also, this estimate of NSAIDs use might be understated as we were not able to capture all the over-the-counter NSAID use. Although we excluded DPN patients with the most common pain or comorbid conditions, it is still not possible conclusively to determine whether this high use of NSAIDs is due to DPN or possibly other comorbidities not excluded. The rates of NSAID use that we observed, which were greater than the rates of use for approved pharmacologic DPN treatment is also troubling given the potential bleeding and cardiovascular risk associated with NSAIDs. 38, 39 In our primary cohort, we did not identify many factors prognostic for DPN pharmacologic treatment, DPN-related opioid use, or first-line opioid use. Insulin use was associated with a higher likelihood of receiving DPN pharmacologic treatment but not opioid use. This may indicate that these patients have severe DPN symptoms and were more likely to receive aggressive pharmacologic management. Similarly, persons with diabetes with complications and those with nephropathy were more likely to use opioids indicating that those with more severe diabetes were more likely to be treated and were more likely to use opioids. However, this finding should be interpreted cautiously, with the exception of 1 sensitivity analysis, these associations were not observed in other sensitivity analyses.
In our sensitivity analyses, which incrementally included DPN patients with excluded conditions, additional factors were associated with DPN-related opioid use and first-line use. Most notably, the presence of multiple pain conditions and higher baseline disease burden were strongly associated with DPN-related opioid use in those sensitivity analyses that included persons with pain conditions. It is possible that clinicians may be prescribing these drugs to manage both the DPN and other painful conditions but without a diagnosis that can be clearly linked to a prescription, this interpretation is only speculative.
We also observed that females were more likely to receive any DPN treatment, but were less likely to receive opioids as a first therapeutic agent for DPN. This may be because females with DPN might have less tolerance for DPN symptoms and more sensitivity towards painful stimuli, leading to higher chances of receiving DPN pharmacologic treatment. 40 On the basis of the nature of claims data, this study has the following limitations. First, our final sample only included 666 patients, and of those only 354 had received DPN treatment. As a result, it is unclear if factors that were not found to be significant in our logistic models using the primary cohort were truly not associated with opioid use or first-line opioid use or there was not adequate power to detect differences. Our sensitivity analyses which were larger identified more factors prognostic for opioid and first-line opioid use. Second, availability of other over the counter pain medications including topical agents such as capsaicin could not be fully captured and our rates or DPN pharmacologic treatment may be understated. Third, in clinical practice, opioids are used for numerous pain conditions, so linking use of opioids for any particular condition is difficult. We restricted the sample to exclude those with pain conditions that are most often associated with DPN drug use to mitigate this and employed a series of sensitivity analyses that relaxed those restrictions and in turn our confidence that the opioid use was for DPN is incrementally diminished. Fourth, we attempted to identify associations between prescriber type and receipt of DPN drugs and opioid prescribing. The assignment of a prescriber type was based on the frequencies of prescriptions written by each prescriber type and it is not known if this was the physician who ultimately was responsible for deciding upon DPN pharmacologic treatments. Finally, our findings may be influenced by the different states' Medicaid and commercial insurance formulary policies, which may steer patients to DPN treatments and these could not be captured in our claims data.
CONCLUSIONS
About 57% of DPN patients remained untreated with pharmacologic therapy a year after an initial DPN diagnosis, which may reflect undertreatment. Despite DPN treatment guidelines that do not recommend opioids as first-line treatment, opioids were among the most frequently prescribed first-line agents. Given the availability of other agents to manage DPN that do not possess the risks of tolerance and potential abuse, efforts to discourage use of opioids as first-line agents should be explored that might include clinical decision support tools, practitioner training, and incorporating multidisciplinary practices with clinical pharmacists. Besides persons with diabetic complications, there were no consistent factors associated with opioid use making it difficult to target patient or provider groups.
